Membrane-associated Proteins Regulating the Complement System: Functions and Deficiencies

References

• Bordet J. Les serums hemolytiques, les anti-toxins et les théories des serums cytoliques. Ann. de l'Institut Pasteur 1900; 14: 257
   Google Scholar
• Yamamoto K. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity. J. Immunol. 1977; 119: 1482
   PubMed Web of Science ®Google Scholar
• Brown S. J., Ramsey J., Hammer C. H., Frank M. M. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. J. Immunol. 1983; 131: 403
   PubMed Web of Science ®Google Scholar
• Hänsch G. M., Hammer C. H., Vanguri E., Shin M. L. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc. Natl. Acad. Sci. USA 1981; 78: 5118
   PubMed Web of Science ®Google Scholar
• Houle J. J., Hoffman E. M. Evidence for restriction of the ability of complement to lyse homologous erythrocytes. J. Immunol. 1984; 133: 1444
   PubMed Web of Science ®Google Scholar
• Shin M. L., Hänsch G. M., Hu V. W., Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J. Immunol. 1986; 136: 1777
   PubMed Web of Science ®Google Scholar
• Fearon D. T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leucocyte, B lymphocyte and monocyte. J. Exp. Med. 1980; 125: 20
   Google Scholar
• Nicholson-Weller A., Burge J., Fearon D. T., Weller P. E., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3-convertase of the complement system. J. Immunol. 1982; 129: 184
   PubMed Web of Science ®Google Scholar
• Hoffmann E. M. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 1969; 6: 391
   PubMedGoogle Scholar
• Schönermark S., Rauterberg E. W., Shin M. L., Loke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane derived protein with C8-binding capacity functions as an inhibitor. J. Immunol. 1986; 136: 1772
   PubMed Web of Science ®Google Scholar
• Zalman L. S., Wood L. M., Müller-Eberhard H. J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc. Natl. Acad. Sci. USA 1986; 83: 6975
   PubMed Web of Science ®Google Scholar
• Cole J., Haisly G. A., Dykman T. R., MacDemott R. R., Atkinson J. P. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leucocytes and cell lines. Proc. Natl. Acad. Sci. USA 1985; 83: 859
   Google Scholar
• Liszewski M. K., Post T. W., Atkinson J. P. Membrane Cofactor Protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 1991; 9: 431
   PubMed Web of Science ®Google Scholar
• Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 1989; 170: 637
   PubMed Web of Science ®Google Scholar
• Sugita Y., Nakano Y., Tamita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J. Biochem. 1988; 104: 633
   PubMed Web of Science ®Google Scholar
• Okada N., Harada R., Fujita T., Okada H. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J. Immunol. 1989; 143: 2262
   PubMed Web of Science ®Google Scholar
• Holguin M. H., Frederick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1989; 84: 7
   PubMed Web of Science ®Google Scholar
• Whitlow M. B., Iida K., Stefanova I., Bernhard A., Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol. 1990; 126: 176
   PubMed Web of Science ®Google Scholar
• Schreiber A. D. Paroxysmal nocturnal hemoglobinuria revisited. N. Engl. J. Med. 1983; 309: 723
   PubMed Web of Science ®Google Scholar
• Rosse W. F. The control of complement activation by the blood cells in paroxysmal nocturnal hemoglobinuria. Blood 1986; 67: 268
   PubMed Web of Science ®Google Scholar
• Devine D. V., Gluck W. L., Rosse W. E., Weinberg J. B. Acute lymphoblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone. J. Clin. Invest. 1987; 79: 314
   PubMed Web of Science ®Google Scholar
• Blaas R., Weber S., Hänsch G. M., Peter H. H. Paroxysmale nachtliche Hamoglobinurie. Klin. Wochenschr. 1990; 68: 247
   PubMedGoogle Scholar
• Parker C. J., Baker P. J., Rosse W. F. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1982; 69: 337
   PubMed Web of Science ®Google Scholar
• Hänsch G. M., Hammer C., Jiji R., Rother U., Shin M. L. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum. Immunobiol. 1983; 164: 118
   PubMed Web of Science ®Google Scholar
• Hu V. W., Nicholson-Weller A. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization. Proc. Natl. Acad. Sci. USA 1985; 82: 5520
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller J. R., March S., Rosenfeld I., Austen K. F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. USA 1983; 80: 5066
   PubMed Web of Science ®Google Scholar
• Pangburn M. K., Schreiber R. D., Trombold J. S., Müller-Eberhard H. J. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J. Exp. Med. 1971; 157: 1983
   Google Scholar
• Hänsch G. M., Schönermark S., Roelcke D. Paroxysmal nocturnal hemoglobinuria type III: Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J. Clin. Invest. 1987; 80: 7
   PubMed Web of Science ®Google Scholar
• Zalman L. S., Wood L. M., Frank M. M., Müller-Eberhard H. J. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 1987; 165: 572
   PubMed Web of Science ®Google Scholar
• Okada N., Harada R., Okada H. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin. Exp. Immunol. 1990; 80: 109
   PubMed Web of Science ®Google Scholar
• Weiler J. M., Daha M. R., Austen K. E., Fearon D. T. Control of the amplification convertase of complement by the plasma protein B1H. Proc. Natl. Acad. Sci. USA 1976; 73: 3268
   PubMed Web of Science ®Google Scholar
• Whaley K., Ruddy S. Modulation of the alternative complement pathway by B1H globulin. J. Exp. Med. 1976; 144: 1147
   PubMed Web of Science ®Google Scholar
• Shin M. L., Gelfand M. C., Nagle R. B., Carlo J. R., Green I., Frank M. M. Localization of receptors for activated complement on visceral epithelial cells of the human renal glomerulus. J. Immunol. 1977; 118: 869
   PubMed Web of Science ®Google Scholar
• Lublin D. M., Atkinson J. P. Decay-accelerating factor: biochemistry, molecular biology, and function. Ann. Rev. Immunol. 1989; 7: 35
   PubMed Web of Science ®Google Scholar
• Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene clusters. Adv. Immunol. 1989; 45: 381
   PubMed Web of Science ®Google Scholar
• Davitz M. A., Low N. G., Nussenzweig V. Release of decay accelerating factor (DAF) from the cell membrane by phosphatidylinositol specific phospholipase C (PIPLC). J. Exp. Med. 1986; 163: 1150
   PubMed Web of Science ®Google Scholar
• Medof M. F., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 1984; 160: 1558
   PubMed Web of Science ®Google Scholar
• Lublin D. M., Coyne K. E. Transfected decay-accelerating factor and membrane cofactor protein protect foreign cells from complement-mediated damage: equal efficiency of phospholipid-anchored and transmembrane forms. Complement Inflamm. 1991; 8: 184, (abstract).
   Google Scholar
• Atkinson J. R., Oglesby T. I., White D., Adams E. A., Liszewski M. K. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin. Exp. Immunol. 1991; 86: 27
   PubMedGoogle Scholar
• Cosio F. G., Sedmak D. D., Mahan I. D., Nahman N. S. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int. 1989; 36: 100
   PubMed Web of Science ®Google Scholar
• Shibata T., Cosio F. G. Expression of cell-associated C3 regulatory proteins (CCRP) on human glomerular cells. JASN 1990; 1: 538
   Google Scholar
• Rother U., Hänsch G. M., Menzel J., Rother K. Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria. Z. Immun.-Forsch. 1974; 148: 172
   Google Scholar
• Rother U., Hänsch G. M., Rother K. Deviated lysis: transfer of complement lytic activity to unsensitized cells. II. Generation of the activity by inulin and by antigen antibody complexes. Z. Immun. Forsch. 1976; 151: 442
   Google Scholar
• Götze O., Müller-Eberhardt H. J. Lysis of erythrocytes by complement in the absence of antibody. J. Exp. Med. 1970; 132: 898
   PubMed Web of Science ®Google Scholar
• Thompson R. A., Rowe D. S. Reactive haemolysis—a distinctive form of red cell lysis. Immunology 1968; 14: 745
   PubMed Web of Science ®Google Scholar
• Rother U., Hänsch G. M., Rauterberg E. W., Jungfer H., Rother K. Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity by low pH or low ionic strength. Z. Immun. Forsch. 1978; 155: 118
   Google Scholar
• Vogt W., Zabern I. V., Hesse D., Nolte R., Haller Y. Generation of an activated form of C5 (C5b like C5) by oxygen radicals. Immunology letters 1986; 14: 209, /87.
   Web of Science ®Google Scholar
• Kirschfink M., Borsos T. Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes. Molecular Immunology 1988; 25: 505
   PubMed Web of Science ®Google Scholar
• Podack E. R., Kolb W. P., Müller-Eberhard H. J. The C5b6 complex: formation, isolation and inhibition of its activity by lipoprotein and the S-protein of human serum. J. Immunol. 1978; 120: 1841, 49.
   PubMed Web of Science ®Google Scholar
• Jenne D., Stanley K. K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J. 1985; 4: 3353
   Web of Science ®Google Scholar
• Lint T. E., Behrends C. L., Gewurz H. Serum lipoproteins and C567-INH activity. J. Immunol. 1977; 119: 883
   PubMed Web of Science ®Google Scholar
• Murphy B. E., Kirszbaum L., Walker I. D., d'Apice A., SP- J. P. J. Clin. Invest. 1988; 81: 1858, 40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis.
   PubMed Web of Science ®Google Scholar
• Murphy B. F., Saunders J. R., O'Bryan M. K., Kirszbaum L., Walker I. D., d'Apice A. J. F. SP-40,40 is an inhibitor of C5b-6 initiated hemolysis. Int. Immunol. 1989; 1: 551
   PubMedGoogle Scholar
• Schönermark S., Filsinger S., Berger B., Hänsch G. M. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase. Immunology 1988; 63: 585
   PubMed Web of Science ®Google Scholar
• Young J. D., Rosse W. F., Hasselkus-Light C. S. The homologous restriction factor is immunologically related to complement components C8 and C9 and to lymphocyte pore-forming protein perforin through cysteine-rich domains. Biochem. Biophys. Res. Comm. 1990; 166: 648
   PubMed Web of Science ®Google Scholar
• Yamamoto H., Blaas R., Nicholson-Weller A., Hansen G. M. Homologous species restriction of the complement-mediated killing of nucleated cells. Immunology 1990; 70: 422–426
   PubMed Web of Science ®Google Scholar
• Meri S., Morgan B. R., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1
   PubMed Web of Science ®Google Scholar
• Zhao J., Rollins S. A., Bothwell A. M., Sims PJ. Amplified gene expression in CD59-transfected CHO cells confers protection against the membrane attack complex of human complement. FASEB J., 5: A1339, 1991 (abstract).
   Google Scholar
• Blaas R., Berger B., Weber S., Peter H. H., Hänsch G. M. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane. J. Immunol. 1988; 140: 3045–51
   PubMed Web of Science ®Google Scholar
• Schieren G., Schönermark M., Wagner C., Blaas-Mautner P., Rother K., Hänsch G. M. Defense mechanisms of human glomerular mesangial cells (GMC) against complement (C) attack. JASN 1990; 1: 536, (abstract).
   Google Scholar
• Rooney I. A., Davies A., Griffiths D., Williams J. D., Davies M., Meri S., Lachmann P. J., Morgan B. P. The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin. Exp. Immunol. 1991; 83: 251
   PubMed Web of Science ®Google Scholar
• Meri S., Walsh L., Davies A., Tone M., Daniels R. H., Morgan B. R., Waldmann H., Lachmann W. J. Tissue distribution and function of protectin (CD59), a complement lysis restricting factor. Complement Inflamm. 1990; 7: 138, (abstract).
   Google Scholar
• Schieren G., Blaas P., Hänsch G. M. Detection of a cytoplasmic form of C8 binding protein (C8bp)in nucleated cells and enhanced expression after stimulation with phorbol ester. Complement Inflamm. 1990; 7: 118, (abstract).
   Google Scholar
• Schieren G., Janssen O., Hänsch G. M. Enhanced expression of the complement-regulatory factor C8 binding protein (C8bp) on U937 cells after stimulation with interleukin - 1β, endotoxin, γ-interferon or phorbol ester. J. Immunol. 1992, in press.
   PubMedGoogle Scholar
• Gordon D. L., Papazakaroudakis H., Averym V., Sadlon T., Arellano A., Okada N. FMLP stimulation and increases in intracellular calcium cause upregulation of neutrophil CD59 (HRF20). Complement Inflamm. 1991; 8: 136, (abstract).
   Google Scholar
• Zhang Z. N., Liu E. K. Clinical features of paroxysmal nocturnal hemoglobinuria (PNH) in China as compared with those in United Kingdom. Chung Hua Nei Ko Tsa Chih 1991; 30: 276
   Google Scholar
• Ham T. H. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: study of the mechanism of hemolysis in relation to acid-base equilibrium. N. Engl. J. Med. 1937; 217: 915
   Google Scholar
• Parker C. J., Baker P. J., Rosse W. F. Comparison of binding characteristics of factor B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes. J. Immunol. 1983; 131: 2484
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A., Douglas M. D., Spice D. B., Austen M. D. Deficiency of the complement regulatory protein, “decay accelerating factor”, on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 1985; 312: 1091
   PubMed Web of Science ®Google Scholar
• Devine D. V., Siegel R. S., Rosse W. F. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J. Clin. Invest. 1987; 79: 131
   PubMed Web of Science ®Google Scholar
• Sims P. J., Rollins S. A., Wiedmer T. Regulatory control of complement on blood platelets. Modulation of blood platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J. Biol. Chem. 1922; 264: 8, 1989
   Google Scholar
• Stern M., Rosse W. F. Two populations of granulocytes in paroxysmal nocturnal hemoglobinuria. Blood 1979; 53: 928
   PubMed Web of Science ®Google Scholar
• Oni S. B., Osunkoya B. O., Kuzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 1970; 36: 145
   PubMed Web of Science ®Google Scholar
• Packmann C. H., Rosenfeld S. I., Jenkins D. E., Thiem P. A., Leddy J. P. Complement lysis of human erythrocytes: differing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. J. Clin. Invest. 1979; 64: 428
   PubMed Web of Science ®Google Scholar
• Chow F. L., Hall S. E., Rosse W. F., Telen M. J. Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria. Blood 1986; 67: 893
   PubMed Web of Science ®Google Scholar
• Shichishima T., Terasawa T., Hashimoto C., Ohto H., Uchida T., Maruyama Y. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br. J. Haematol. 1991; 78: 545
   PubMed Web of Science ®Google Scholar
• Rosse W. E., Hoffman S., Campbell M., Borowitz M., Moore J. Q., Parker C. J. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br. J. Haematol. 1991; 79: 99
   PubMed Web of Science ®Google Scholar
• Kawakami Z., Ninomiya H., Tomiyama J., Abe T. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils. Br. J. Haematol. 1990; 74: 508
   PubMed Web of Science ®Google Scholar
• Selvaraj P., Dustin M. L., Silber R., Low M. G., Springer T. A. Deficiency of lymphocyte-function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlated and evidence for a phosphatidylinositol membrane anchor. J. Exp. Med. 1987; 166: 1011
   PubMed Web of Science ®Google Scholar
• Selvaraj P., Rosse W. E., Silber R., Springer T. A. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333: 565
   PubMed Web of Science ®Google Scholar
• Simmons D. L., Tan S., Tenen D. G., Nicholson-Weller A., Seed B. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 1989; 73(1)284
   PubMed Web of Science ®Google Scholar
• Hänsch G. M., Weller P. F., Nicholson-Weller A. Release of C8bp by phosphatidylinositol-specific phospholipase C. Blood 1988; 72: 1089
   PubMed Web of Science ®Google Scholar
• Lewis S. M., Dacie J. V. Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal hemoglobinuria. Br. J. Haematol. 1965; 11: 549
   PubMed Web of Science ®Google Scholar
• Auditore J. V., Hartmann R. C., Flexner J. M., Balchum O. J. The erythrocyte acetylcholinesterase enzyme in paroxysmal nocturnal hemoglobinuria. Arch. Pathol. 1960; 69: 534
   PubMedGoogle Scholar
• Chow F. L., Telen M. J., Rosse W. F. The acetylcholinesterase in paroxysmal nocturnal hemoglobinuria: Evidence that the enzyme is absent from the cell membrane. Blood 1985; 66: 940
   PubMed Web of Science ®Google Scholar
• Stafford H. A., Tykocinski M. L., Lublin D. M., Holers V. M., Rosse W. F., Atkinson J. R., Medof M. E. Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc. Natl. Acad. Sci. USA 1988; 85: 880
   PubMed Web of Science ®Google Scholar
• Moore J. C., Frank M. M., Müller-Eberhard H. J., Young N. S. Decay accelerating factor is present in PNH erythroid progenitors and lost during erythropoiesis in vitro. J. Exp. Med. 1985; 162: 1182
   PubMed Web of Science ®Google Scholar
• Nakakuma H., Kawaguchi T., Horikawa K., Hidaka M., Yonemura Y., Kawakita M., Kagimoto T., Iwamori M., Nagai Y., Takatsuki K. Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1990; 85: 1456
   PubMed Web of Science ®Google Scholar
• Medof M. E., Gottlieb A., Kinoshita T., Hall S., Silber R., Nussenzweig V., Rosse W. F. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocyte. J. Clin. Invest. 1987; 80: 165
   PubMed Web of Science ®Google Scholar
• Parker C. J., Soldato C. M., Rosse W. F. Abnormality of glycophorin-α on paroxysmal nocturnal hemoglobinuria erythrocytes. J. Clin. Invest. 1984; 73: 1130
   PubMed Web of Science ®Google Scholar
• Yamashina M., Ueda E., Kinoshita T., Takami T., Ojima A., Ono H., Tanaka H., Kondo N., Orii T., Okada N., Okada H., Luone K., Kitani T. Inherited complete deficiency of 20 kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemiglobinuria. N. Engl. J. Med. 1990; 323: 1184
   PubMed Web of Science ®Google Scholar
• Noda M., Yoon K., Rodon G. A., Koppel D. E. High lateral mobility of endogenous and transfected alkaline phosphatase: a phosphatidyl-inositol-anchored membrane protein. J. Cell Biol. 1987; 105: 1671
   PubMed Web of Science ®Google Scholar
• Altman A., Mustelin T., Coggeshall K. M. T lymphocyte activation: a biological model of signal transduction. Critical Reviews in Immunology 1990; 10: 347
   PubMed Web of Science ®Google Scholar
• Stiernberg J., Low M. G., Flaherty L., Kincade P. W. Removal of lymphocyte surface molecules with phosphatidyl-inositol-specific phospholipase C: Effects on mitogen responses. J. Immunol. 1987; 138: 3877
   PubMed Web of Science ®Google Scholar
• Tomiyama J., Ninomiya H., Abe T. Enhanced complement susceptibility and dysfunction of lymphocytes in paroxysmal nocturnal haemoglobinuria (PNH). Br. J. Haematol. 1990; 76: 540
   PubMed Web of Science ®Google Scholar
• Davis L. S., Patel S. S., Atkinson J. P., Lipsky P. E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 1988; 141: 2246
   PubMed Web of Science ®Google Scholar
• Rock K. L., Yeh E. T. H., Gramm C. F., Haber S. I., Reiser H., Benacerraf B. TAP, a novel T cell-activating protein involved in the stimulation of MHC-restricted T lymphocytes. J. Exp. Med. 1986; 163: 315
   PubMed Web of Science ®Google Scholar
• Levy L., Lepow I. H. Assay and properties of serum inhibitor of C1-esterase. Proc. Soc. Exp. Biol. Med. 1959; 101: 608
   PubMed Web of Science ®Google Scholar
• Scharfstein J., Ferreira A., Gigli I., Nussenzweig V. Human C4-binding protein, I. Isolation and characterization. J. Exp. Med. 1978; 148: 207
   PubMed Web of Science ®Google Scholar
• Nelson R. A., Jensen J., Gigli I., Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea pig serum. Immunochemistry 1966; 3: 111
   PubMedGoogle Scholar
• Nilsson V. R., Müller-Eberhard H. J. Isolation of BIF-globulin from human serum and its characterization as the fifth component of complement. J. Exp. Med. 1965; 122: 277
   PubMed Web of Science ®Google Scholar
• Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J. Exp. Med. 1977; 146: 257
   PubMed Web of Science ®Google Scholar
• Quigg R. J. Isolation of a novel complement regulatory protein (GCRP) from cultured rat glomerular epithelial cells (GEC). JASN 1990; 1: 535, (abstract).
   Google Scholar
• Watts M. J., Dankert J. R., Morgan B. F. Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids. Biochem. J. 1990; 265: 471
   PubMed Web of Science ®Google Scholar
• Brauch H., Roelcke D., Rother U. Glycophorin A inhibits lysis by the complement attack phase. Immunobiol. 1983; 165: 115
   PubMed Web of Science ®Google Scholar
• Schieren G., Hänsch G. M. CD59 and C3 binding protein (C8bp) are biochemically distinct proteins. Complement Inflamm. 1991; 8: 219, (abstract).
   Google Scholar
• Simmons D. L., Tan S., Tenen D. G., Nicholson-Weller A., Seed B. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 1989; 73: 284
   PubMed Web of Science ®Google Scholar
• Van der Schoot C. E., Huizinga T. W., van-'t Veer-Korthof E. T., Wijmans R., Pinkster J., von dem Borne A. E. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76: 1853
   PubMed Web of Science ®Google Scholar
• Schubert J., Uciechowski P., Delany R., Tischler H. J., Kolanus W., Schmidt R. E. The PIG-anchoring defect in NK lymphocytes of PNH patients. Blood 1990; 76: 1181
   PubMed Web of Science ®Google Scholar
• Jost C. R., Gaillard M. L., Fransen J. A. M., Daha MR., Ginsel L. A. Intracellular localization of glycosyl-phosphatidylinositol-anchored CD67 and FcRIII (CD16) in affected neutrophil granulocytes of patients with paroxysmal nocturnal hemoglobinuria. Blood 1991; 78: 3030
   PubMed Web of Science ®Google Scholar
• Nakakuma H., Kawaguchi T., Horikawa K., Hidaka M., Yonemura Y., Kawakita M., Kagimoto T., Iwamori M., Nagai Y., Takatsuki K. Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1990; 85: 1456
   PubMed Web of Science ®Google Scholar
• Tsien R. Y., Pozzan T., Rink T. J. Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator. The Journal of Cell Biology 1982; 94: 326
   Web of Science ®Google Scholar